本帖最后由 老马 于 2013-3-13 13:43 编辑
+ a' T0 z5 M1 M- ]8 @/ t/ E. P. v9 ?0 G9 F1 H
健择(吉西他滨)+顺铂+阿瓦斯汀
) N2 U) v( j- ~ r+ I9 g Gemzar +Cisplatin + Avastin
1 r2 M0 \2 e5 O0 A' ?' H2 ohttp://annonc.oxfordjournals.org/content/21/9/1804.full
# p* d( k4 C/ H' J# BOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ! ^# _2 \* m, N& `. W' ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 M# b3 o8 C( C0 _. I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" f4 g; K$ O! j! A. g# W% G$ Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1018)
* s8 c& W, a* Y1 t
华为网盘附件:6 x$ l- y; F) X) i
【华为网盘】ava.JPG
/ f% I6 e& B# |9 Z- R5 B |